Pharma Sctors

TPG acquires 35% in SCHOTT Poonawalla, SII retains minority stake

SCHOTT Pharma keeps 50% stake in Indian JV as TPG joins with Novo Holdings to support global pharma supply chain growth; deal expected to close in H1 2025

US pharma tariffs would raise US drug costs by $51 bn annually: Report

Pharmaceutical products have long been spared from trade wars due to the potential harms, but he has repeatedly threatened a 25 per cent tariff on pharmaceutical imports

Here's why Zydus Lifesciences share price popped 3% in trade on March 19

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg

Glenmark recalls 1.5 million bottles of ADHD medication in US: USFDA

Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the US market, according to the US health regulator. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths. The company is recalling the affected lot due to "CGMP Deviations", the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. The recall is due to "presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit," it added. New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the made-in-India product in strengths ranging from 10 mg to 100 mg, USFDA stated. The company initiated the Class II recall on January 29 this year. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medic

Distributed manufacturing may become the future trend: Pharma Inc

Volumes need to be high to justify relocation of manufacturing; strategic decisions cannot be based on current tariff structure

What products and services may see their prices change in Budget 2025?

The Finance Minister is expected to prioritise economic growth, domestic manufacturing, and offer relief to consumers in the upcoming budget to address inflation, fiscal consolidation, and job creatio

Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

Pharma dept reprimands AbbVie Healthcare for unethical marketing practices

Company sponsored 'extravagant pleasure trips' abroad of 30 doctors, violating code on pharmaceutical marketing practices

Senores pharma IPO subscribed 1.78 times on Day 1, retail demand strong

The initial share sale of Senores Pharmaceuticals Ltd got subscribed 1.78 times on Friday, the first day of bidding. The Initial Public Offer (IPO) received bids for 1,51,51,550 shares against 85,34,681 shares on offer, according to NSE data. Retail Individual Investors (RIIs) part fetched 7.19 times subscription while the quota for non-institutional investors got subscribed 1.67 times. Qualified Institutional Buyers (QIBs) quota got subscribed 1 per cent. Senores Pharmaceuticals Ltd on Thursday said it has secured nearly Rs 261 crore from anchor investors. The Rs 582-crore IPO will conclude on December 24. The IPO has a price range of Rs 372-391 per share. The Ahmedabad-based company's IPO is a combination of fresh issuance of shares worth Rs 500 crore and an offer for sale (OFS) of up to 21 lakh shares valued Rs 82.11 crore, by promoters and other selling shareholders, at the upper end of the price band. Proceeds from the fresh issue will be utilised for setting up a manufactur

Abbott India share rises 3% as JPMorgan ups target to Rs 31,500; details

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed

The uptick in Piramal Pharma share price came after domestic brokerage JM Financial initiated coverage with 'Buy' for a target price of Rs 340

Here's why Gland Pharma share was up 3% on December 3; details here

The uptick in Gland Pharma share came after the company said that it has received approval from the United States Food and Drug Administration (US FDA) for Latanoprost Ophthalmic Solution

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Akums Drugs tanks 10%, falls below issue price on weak Q2 earnings

In two days, the stock price of Akums Drugs has declined 19% to Rs 645.30 and fallen below its issue price of Rs 679 per share.

Suven, Cohance aim to double combined biz revenue to Rs 6,000 cr by FY29

Merger-bound Suven Pharmaceuticals and Cohance Lifesciences aim to more than double their combined revenue to around Rs 6,000 crore by FY29 by undertaking both organic and inorganic growth routes, a top company official said. The entities reported a combined revenue of Rs 2,392 crore in FY24. The merged entity aims to put in place an aggressive plan to more than double revenue to Rs 6,000 crore by FY29 through both organic and inorganic growth routes, Suven Pharma Managing Director Prasada Raju said. The merger between Suven and Cohance has received approval from both NSE & BSE. As directed by National Company Law Tribunal (NCLT), the shareholders meeting of both Suven Pharmaceuticals and Cohance Lifesciences amalgamation will be held on November 28, 2024. Once finalised and approved, the combined entity will focus on three core growth drivers: pharma CDMO, specialty chemicals CDMO, and active pharmaceutical ingredients (APIs). "Together, we're building a powerhouse poised to ...

Here's why Natco Pharma share price gained over 4% on October 7; details

Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)

CVS Health likely to explore options including potential break-up

CVS is led by healthcare industry veteran Karen Lynch, who previously headed the Aetna unit and is temporarily overseeing the business with Chief Financial Officer Tom Cowhey

Regulatory, policy reforms crucial for future of India's pharma R&D: Report

India's regulatory and policy reforms are crucial for shaping the future of pharmaceutical research and development by streamlining approval processes, strengthening IP protections and incentivising innovation, as several policy challenges continue to hinder the growth of R&D in the sector, according to a report. As the country modernises its regulatory framework and enhances collaboration with global regulatory agencies, India is well-positioned to become a global leader in pharmaceutical innovation, as per the report by Deloitte and industry chamber ASSOCHAM. It acknowledged that India's pharmaceutical ecosystem is transforming significantly, supported by comprehensive regulatory and policy reforms to foster innovation and growth. The regulatory framework, which governs drug discovery, development and commercialisation, is being actively enhanced to streamline approval processes, increase transparency and reduce barriers to entry for innovative products. However, the report ...